Literature DB >> 6763002

Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and in Mitsuda-negative contacts.

J Convit, N Aranzazu, M Ulrich, M E Pinardi, O Reyes, J Alvarado.   

Abstract

A total of 529 weak or non-reactors to M. leprae, including Mitsuda-negative contacts and patients with leprosy, were vaccinated once or repeatedly, as necessary, with a mixture of 6 x 10(8) purified, heat-killed M. leprae and 0.01 mg to 0.2 mg of viable BCG. Clinical, histopathological and immunological criteria were used to evaluate the response of these individuals. Clinical changes, including sharper definition of borders and progressive flattening and regression of lesions, were observed in 57% of the active LL cases and 76% of the active BL cases. Histopathological study revealed infiltration of the lesions by mononuclear cells, appearance of epithelioid differentiation, and fragmentation of the microorganisms. Delayed-type skin tests with soluble antigen from purified M. leprae became positive in significant numbers of each group studied. These results demonstrate the efficacy of combined immunotherapy in low-resistance forms of leprosy and potential utility in the immunoprophylaxis of the disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6763002

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  11 in total

1.  Serological monitoring of previously treated lepromatous patients during a course of multiple immunotherapy treatments with heat-killed Mycobacterium leprae and BCG.

Authors:  J T Douglas; D S Hirsch; T T Fajardo; L S Guido; P R Klatser
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

2.  Human T-cell clones with reactivity to Mycobacterium leprae as tools for the characterization of potential vaccines against leprosy.

Authors:  F Emmrich; S H Kaufmann
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

3.  An immunodominant 30-kDa antigen of a candidate anti-leprosy vaccine, Mycobacterium w, shares T and B cell determinants with M. leprae and M. tuberculosis.

Authors:  A Yadava; R Mukherjee
Journal:  Med Microbiol Immunol       Date:  1993-11       Impact factor: 3.402

Review 4.  Leprosy.

Authors:  R C Hastings; T P Gillis; J L Krahenbuhl; S G Franzblau
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

5.  Immunization against leprosy: progress and prospects.

Authors:  S K Noordeen; H Sansarricq
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

6.  Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by antigen-specific T cell anergy.

Authors:  M Ulrich; V Rodriguez; M Centeno; J Convit
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

7.  Mycobacterium bovis BCG-induced protection against cutaneous and systemic Leishmania major infections of mice.

Authors:  A H Fortier; B A Mock; M S Meltzer; C A Nacy
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

8.  Immunological suppression by human CD8+ T cells is receptor dependent and HLA-DQ restricted.

Authors:  P Salgame; J Convit; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

9.  Learning from lesions: patterns of tissue inflammation in leprosy.

Authors:  R L Modlin; J Melancon-Kaplan; S M Young; C Pirmez; H Kino; J Convit; T H Rea; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

10.  Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy.

Authors:  K M McAveney; L G Gomella; E C Lattime
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.